Search hospitals > California > Duarte
City of Hope Comprehensive Cancer Center
Claim this profileDuarte, California 91010
Global Leader in Lymphoma
Global Leader in Skin Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Uterine Tumors
Conducts research for Cancer
2114 reported clinical trials
157 medical researchers
Summary
City of Hope Comprehensive Cancer Center is a medical facility located in Duarte, California. This center is recognized for care of Lymphoma, Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma, Uterine Tumors, Cancer and other specialties. City of Hope Comprehensive Cancer Center is involved with conducting 2,114 clinical trials across 1,132 conditions. There are 157 research doctors associated with this hospital, such as Daneng Li, MD, Anna Pawlowska, MD, Mark Agulnik, and Vincent Chung, MD.Area of expertise
1Lymphoma
Global LeaderStage IV
Stage II
Stage I
2Skin Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Daneng Li, MDCity of Hope5 years of reported clinical research
Expert in Liver Cancer
Expert in Skin Cancer
27 reported clinical trials
42 drugs studied
Anna Pawlowska, MDCity of Hope Comprehensive Cancer Center7 years of reported clinical research
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Uterine Tumors
26 reported clinical trials
63 drugs studied
Mark AgulnikCity of Hope3 years of reported clinical research
Studies Soft Tissue Sarcoma
Studies Cancer
23 reported clinical trials
34 drugs studied
Vincent Chung, MDCity of Hope Medical Center2 years of reported clinical research
Expert in Pancreatic Cancer
Expert in Stomach Cancer
21 reported clinical trials
33 drugs studied
Clinical Trials running at City of Hope Comprehensive Cancer Center
Prostate Cancer
Breast Cancer
Ovarian Cancer
Lymphoma
Skin Cancer
Lung Cancer
Kidney Cancer
Multiple Myeloma
Breast cancer
Pancreatic Cancer
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at City of Hope Comprehensive Cancer Center?
Where is City of Hope Comprehensive Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does City of Hope Comprehensive Cancer Center accept?
What awards or recognition has City of Hope Comprehensive Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.